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Abstract
Background: Comfrey (Symphytum officinale) is a perennial plant and has been consumed by
humans as a vegetable, a tea and an herbal medicine for more than 2000 years. It, however, is
hepatotoxic and carcinogenic in experimental animals and hepatotoxic in humans. Pyrrolizidine
alkaloids (PAs) exist in many plants and many of them cause liver toxicity and/or cancer in humans
and experimental animals. In our previous study, we found that the mutagenicity of comfrey was
associated with the PAs contained in the plant. Therefore, we suggest that carcinogenicity of
comfrey result from those PAs. To confirm our hypothesis, we compared the expression of genes
and processes of biological functions that were altered by comfrey (mixture of the plant with PAs)
and riddelliine (a prototype of carcinogenic PA) in rat liver for carcinogenesis in this study.
Results: Groups of 6 Big Blue Fisher 344 rats were treated with riddelliine at 1 mg/kg body weight
by gavage five times a week for 12 weeks or fed a diet containing 8% comfrey root for 12 weeks.
Animals were sacrificed one day after the last treatment and the livers were isolated for gene
expression analysis. The gene expressions were investigated using Applied Biosystems Rat Whole
Genome Survey Microarrays and the biological functions were analyzed with Ingenuity Analysis
Pathway software. Although there were large differences between the significant genes and
between the biological processes that were altered by comfrey and riddelliine, there were a
number of common genes and function processes that were related to carcinogenesis. There was
a strong correlation between the two treatments for fold-change alterations in expression of drug
metabolizing and cancer-related genes.
Conclusion:  Our results suggest that the carcinogenesis-related gene expression patterns
resulting from the treatments of comfrey and riddelliine are very similar, and PAs contained in
comfrey are the main active components responsible for carcinogenicity of the plant.
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Background
Comfrey (Symphytum officinale) is consumed by humans
as a vegetable and a tea. It has been used as an herbal med-
icine for more than 2000 years to treat broken bones, ten-
don damage, ulcerations in the gastrointestinal tract, lung
congestion, and joint inflammation, and to promote
wound healing [1]. It, however, has been reported that
comfrey is hepatotoxic in livestock and humans, and car-
cinogenic in experimental animals. Comfrey induced
hepatic veno-occlusive lesion (VOD) in humans [2-4] and
hepatocellular adenomas and hemangioendothelial sar-
comas in rats [5]. Therefore, the regular use of comfrey is
a potential health risk for development of liver cancers. In
2001, the US Food and Drug Administration requested
voluntary compliance for the removal of products con-
taining comfrey [6].
It is still not clear about the mechanism of tumor induc-
tion by comfrey because comfrey is a mixture of many dif-
ferent substances and the active components responsible
for the carcinogenesis have not been identified. It has
been suggested that the induction of hepatic tumors has
been associated with the pyrrolizidine alkaloids (PAs)
that are present in comfrey [7-9] since PAs are genotoxic
and carcinogenic in liver [10,11]. Recently, we demon-
strated that the PAs in the comfrey plant appear to be
responsible for mutation induction in rat liver [12]. Muta-
tions are involved in the etiology of cancer [13]. Research
results in molecular cancer genetics have identified inher-
ited and somatic cell mutations associated with cancer in
oncogenes, tumor suppressor genes, DNA repair genes
and other related genes [14-17]. Therefore, we hypothe-
size that PAs contained in comfrey are the main active
components resulting in tumors in liver.
Riddelliine is one of the tumorigenic PAs and has been
studied as a prototype of PA. The toxicity and carcino-
genicity of riddelliine have been studied by the National
Toxicological Program (NTP) [18-20], and the mecha-
nism of riddelliine-induced tumorigenicity in experimen-
tal animals has been studied at the National Center for
Toxicological Research (NCTR) [21-27]. Results showed
that (1) riddelliine was metabolized to the major metab-
olites 6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine
(DHP) and riddelliine N-oxide; (2) DHP-derived DNA
adducts were formed both in vivo and in vitro; (3) G:C →
T:A transversions were the major type of mutation
induced in the liver of riddelliine-treated rats; and (4) rid-
delliine caused liver tumors in male mice and both sexes
of rats, mononuclear cell leukemia in rats, and lung neo-
plasms in female mice.
DNA microarray, a key advanced technology, has devel-
oped rapidly because of its ability to examine the expres-
sion levels of thousands of genes simultaneously. It is
used increasingly for identifying biomarkers, elucidating
patterns of gene expression, and understanding the mech-
anism of disease and toxicity. Toxicogenomics applies
high through-put genomics tools to the study of toxicol-
ogy and gene expression microarrays have been used
extensively [28]. The interpretation of gene expression
data, however, can be complicated by the gene expression
alterations caused by environmental factors such as diet
[29] and time of day [30,31]. That is, it can be difficult to
discern toxin-specific gene expression changes from those
due to environmental effects. This can be complicated fur-
ther when the test article is a complex food such as
comfrey.
To examine the possible PA-induced affects on gene
expression caused by comfrey, the gene expression pro-
files in the livers of comfrey-treated rats were compared to
the gene expression profiles from rats treated with the
purified PA riddelliine. The correlation of the gene expres-
sion and biological functions related to carcinogenesis
between the two treatments were explored.
Results and discussion
Previously, we investigated the mutagenicity of comfrey
and riddelliine in rats [26,32] under conditions which
have been shown to result in liver tumors [5,20]. In the
original mutation studies, 8% comfrey treatment induced
about a 4-fold higher mutant frequency (MF) over the
control group [32], while 1 mg/kg riddelliine exposure
resulted in about a 3-fold increase in MF compared to
controls [26]. In these studies, the rats were exposed to the
compounds for 12 weeks and then sacrificed. No tumors
were visible at this time in our study, although Hirono et
al. reported that liver tumors developed in the rats as early
as 7 weeks after initiation of feeding comfrey [5]. The
mutation spectra for comfrey- and riddelliine-treated rats
were significantly different from the controls, but there
was no significant difference between the spectra for
comfrey and riddelliine. G:C → T:A transversion (35–
42%) was the major type of mutation in both comfrey
and riddelliine treated rats, with 8–17% tandem base sub-
stitutions [12]. These mutational data from comfrey-
treated rats suggests that PAs in the plant are responsible
for mutation induction and tumor initiation in rat liver.
To further investigate the effects of comfrey and riddelli-
ine on gene expression changes in liver, microarray analy-
sis was performed on liver samples from these high-dose
groups. The details of each experiment and gene expres-
sion analysis were reported previously [32,33]. In the
present study, gene expression alterations caused by expo-
sure to comfrey were compared to those caused by expo-
sure to the representative PA riddelliine.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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Comparison of gene expression profiles induced by 
comfrey and riddelliine
The intensities of the whole rat gene data were normalized
by quantile normalization and then analyzed by Hierar-
chical Cluster Analysis (HCA) and Principal Component
Analysis (PCA) to visualize clusters of samples corre-
sponding to the different treatments (Figures 1 and 2).
The result of the HCA of the gene expression data is shown
in Figure 1, and shows that samples were grouped
together according to the treatments. There were clear sep-
arations between of the control, comfrey-treated, and rid-
delliine-treated groups. The gene expression pattern due
to comfrey exposure was distinct from that due to riddel-
liine exposure (Figure 2), possibly reflecting the effects of
many other substances in comfrey other than PAs [9]. This
difference is expected to be the result of different proper-
ties of two chemicals including pharmacological and tox-
icological effects.
The differentially expressed genes between the treatment
and control groups were identified based on simple t-test.
The criteria used to classify a gene as differentially
expressed were that there was at least a two-fold change in
the gene expression compared to the controls and a P-
value less than 0.01 for the fold-change difference. By
locus link ID, a total of 1814 genes from the comfrey treat-
ment and 639 genes from the riddelliine treatment satis-
fied the requirements; both with about equal numbers of
up- and down-regulated genes in response to the treat-
ment [32,33]. The number of genes whose expression was
altered by comfrey was much higher than that by riddelli-
ine, possibly due to the fact that comfrey is a complex mix-
ture of biologically active compounds. By locus link ID,
there were 302 genes that were common between comfrey
and riddelliine; the majority of these common genes
Hierarchical Cluster Analysis (HCA) of expression profiles  for control, 8% comfrey-fed, and 1 mg/kg riddelliine treated  groups Figure 1
Hierarchical Cluster Analysis (HCA) of expression 
profiles for control, 8% comfrey-fed, and 1 mg/kg rid-
delliine treated groups. The log2 intensity of the entire 
gene set was scaled by Z-score transformation, and then 
these values were hierarchically clustered using Euclidean 
distance metric and average linkage. Each column represents 
the results from an individual animal. CTR, control; CFY, 
comfrey treatment; RDL, riddelliine treatment.
Principal Component Analysis (PCA) of expression profiles  for control, 8% comfrey-fed, and 1 mg/kg riddelliine treated  groups Figure 2
Principal Component Analysis (PCA) of expression 
profiles for control, 8% comfrey-fed, and 1 mg/kg rid-
delliine treated groups. The intensity of the entire gene 
set was used, and no specific cut off was applied.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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(90%, 273 genes) were regulated in the same direction
(Figure 3). Since PAs generally produce the same types of
DNA adducts [10] and both comfrey and riddelliine have
similar mutational spectra [12,32], it would be expected
that the common genes altered by riddelliine and comfrey
in this study may contribute to PA-induced toxicity.
Common drug metabolizing genes induced by comfrey and 
riddelliine
A striking feature of the biotransformation enzymes is that
their activities can be induced following exposure of
chemicals or drugs. Therefore, examination of drug
metabolizing genes (DMGs) can provide important phar-
macological information, with potential clinical and tox-
icity implications for a given chemical. Liver is the major
organ for biotransformation of xenobiotics and drugs,
and PAs require metabolic activation to exert their biolog-
ical and toxicological effects. Study and comparison of
these genes altered by comfrey and riddelliine can provide
us valuable information about common mechanisms on
PAs' biotransformation and metabolisms. Also, in these
steps PAs are activated into carcinogen, initiating the car-
cinogenesis. Therefore, we focused our investigation on
the expression changes of DMGs. There were 45 and 87
DMGs up- or down-regulated by the treatment of riddelli-
ine and comfrey, when a cut off of 2-fold change and P <
0.01 were used as the criteria to select genes. The expres-
sions of 22 of these genes were altered by both comfrey
and riddelliine, and are detailed in Table 1. The changed
expression of each gene was always in the same direction
for the 2 compounds. These commonly regulated DMGs
were grouped into the three drug metabolism phases
(phase I, II and III).
There are postulated to be three phase 1 pathways for the
metabolism of PA; (1) Oxidation via cytochrome P450
(Cyp), (2) N-oxidation via flavin-containing monooxyge-
nases (Fmo), and (3) hydrolysis via carboxylesterases.
Hepatic cytochrome P450, Cyp3a and Cyp2b isoforms,
were the major metabolizing enzymes involved in PA
metabolism in humans [10]. One gene of the Cyp2b fam-
ily (Cyp2b15) and three genes of the Cyp3a family
(Cyp3a2, 3a9 and 3a18) were contained on the microar-
ray. Although riddelliine elevated the level of Cyp3a9
RNA, no significant changes in the expression of these
genes was induced by both riddelliine and comfrey expo-
sure in our study. However, a significant induction of
Cyp2c12  (Cyp2c40) was found with the expression
increased by 8.7- and 42-fold by the treatments with
comfrey and riddelliine, respectively (Table 1). This sug-
gests that Cyp2c may play an important role in metaboliz-
ing comfrey and riddelliine in addition to Cyp3a and 2b.
Flavin-containing monooxygenases were reported to be
involved in the biotransformation of PAs to the N-oxide
metabolites [34], and N-oxidation appears to be one of
the crucial pathways in determining the toxicity of PAs.
However, it is not well known which particular family
member contributes to this metabolism and toxicity.
Among five flavin-containing monooxygenase genes
(Fmo1-5) contained on microarray, Fmo5 was induced
about 4-fold by both comfrey and riddelliine treatments.
Hydrolysis of PAs is considered to be a major detoxifica-
tion pathway in phase I. As shown in Table 1, carboxyleste-
rase 2 (Ces2) was induced by the treatments of comfrey
and riddelliine in our study. Our results not only confirm
the findings reported in the literature but also provide
additional detail that Fmo5 may be the form of flavin-
containing monooxygenases family involved in N-oxida-
tion and carboxylesterase 2 may play a role in hydrolysis
of these chemicals.
Phase II and phase III enzymes usually function as detox-
ication. Phase II enzymes involve in conjugation of the
polar functional groups of phase I metabolites and phase
III enzymes are transporters for these metabolites. In gen-
eral, exposure to some xenobiotics can trigger cellular
"stress" response leading to an increase in the gene expres-
sion of phases II and III, which ultimately enhances the
elimination and clearance of these xenobiotics. Treatment
with comfrey and riddelliine has been shown to alter the
expression of a number of phases II and III genes along
with phase I genes (Table 1). The expression of the glutath-
ione S-transferase, alpha 3 (Gsta3) gene increased 22- and
13-fold over the control with comfrey and riddelliine
treatment, respectively. Glutathione S-transferases are
Numbers of differentially expressed genes (DGEs) regulated  by riddelliine and comfrey treatment Figure 3
Numbers of differentially expressed genes (DGEs) 
regulated by riddelliine and comfrey treatment. A 
gene was identified as differentially expressed if the fold-
change was greater than 2 (up or down) and the P-value was 
less than 0.01 in comparison to the control group. The color 
in green refers to the number of genes whose expressions 
were significantly altered by both comfrey and riddelliine.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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major phase II detoxification enzymes found mainly in
the cytosol. It has been reported that PAs can be conju-
gated with glutathione by these enzymes, reduce glutath-
ione concentrations in liver, and increase the activity of
these conjugation enzymes after PAs treatment [35-37].
This result is consistent with those previously studied. In
the phase III genes, ATP-binding cassette,  sub-family B
(Abcb1) was induced by comfrey and riddelliine 97- and
11-fold over the control, respectively. No publications
have been found about the relationship between PA treat-
ment and induction of ATP-binding cassette. Future
research is encouraged for the role of ATP-binding cassette
in PAs' metabolism and carcinogenesis.
Not surprisingly, there were more DMGs altered by
comfrey treatment than those by riddelliine treatment.
This may be because comfrey is a mixture of many sub-
stances in addition to PAs, and these other substances may
be involved in the induction of other DMGs. Nearly 50%
of DMGs altered by the treatment with riddelliine were
also found altered by the treatment with comfrey. It
should be note that all of these 22 DMGs regulated by
both chemicals changed in the same direction (Table 1).
The gene expression similarity between the two treat-
ments was further assessed by calculating the correlation
coefficients of the log2 fold changes. The result is dis-
played as a scatter plot in Figure 4. The correlation coeffi-
cient was 0.72, indicating a fairly good agreement
between the two treatments and suggesting that the toxic-
ity of comfrey results from activation of PA. Although the
process of drug metabolism is complicated, our results at
least indicate that there is a common mechanism of drug
metabolism involved in these two chemical treatments.
Common biological processes and genes associated with 
carcinogenesis
The Ingenuity Pathway Analysis Knowledge database,
which provides a classification of gene products into
molecular functions, biological processes, and cellular
components, was used to help understand the biological
consequences of exposure to comfrey or riddelliine. Bio-
logical process was examined for the genes from comfrey
and riddelliine individually, and the software placed the
processes into functional processes or categories such as
cancer and cell death. After a cut off of P  < 0.01, we
observed that there were 83 and 118 functional processes
for riddelliine and comfrey treatments, respectively.
Among them, 46 of the function processes were altered by
both comfrey and riddelliine, which was about half of the
function processes altered by riddelliine and one-third of
the function processes altered by comfrey (Figure 5). The
top categories for these functions are listed in Table 2,
including cancer, cell death, cell morphology, cell-to-cell
signaling and interaction, and tissue development. These
Table 1: Genes involved in drug metabolism altered by comfrey and riddelliine treatments in liver
Gene symbol Gene description Locus link ID Fold changea
Comfrey Riddelliine
Phase I metabolism
Ces2 carboxylesterase 2 (intestine, liver) 171118 10.4 2.4
Cyp2c cytochrome P450, subfamily IIC 29277 -24.3 -270.3
Cyp2c40 cytochrome P450, family 2, subfamily c 25011 8.7 42.3
Cyp2e1 cytochrome P450, family 2, subfamily e 25086 2.2 2.1
Fmo5 flavin containing monooxygenase 5 246248 4.1 4.2
Phase II metabolism
Gsta3 glutathione S-transferase, alpha 3 14859 22.5 13.4
Inmt indolethylamine N-methyltransferase 21743 -29.3 -11.7
Nqo1 NAD(P)H dehydrogenase, quinone 1 24314 5.0 2.6
Sult1c1 sulfotransferase family, cytosolic,1C, member1 65185 -2.7 -3.2
Phase III metabolism
Abcb1 ATP-binding cassette, sub-family B 24646 97.0 11.3
Abcb9 ATP-binding cassette, sub-family B, member 9 63886 -5.0 -2.7
Abcc3 ATP-binding cassette, sub-family C, member 3 140668 25.1 10.8
Abcc8 ATP-binding cassette, sub-family C, member 8 25559 -9.7 -2.6
Atp13a5 ATPase type 13A5 268878 -3.6 -4.1
Slc13a5 solute carrier family 13, member 5 266998 -2.9 -2.4
Slc16a4 solute carrier family 16, member 4 229699 -2.8 -4.9
Slc22a6 solute carrier family 22, member 6 29509 -3.7 -2.4
Slc22a8 solute carrier family 22, member 8 83500 -12.2 -833.3
Slc25a21 solute carrier family 25, member 21 171151 4.4 2.7
Slc25a30 solute carrier family 25, member 30 67554 -4.5 -2.7
aThe symbol of minus (-) means down-regulation, and the P-value for all genes is less than 0.01.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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results suggest that common mechanism(s) may be
responsible for the toxicity of both comfrey and riddelli-
ine.
The finding that both comfrey and riddelliine treatments
trigger gene expression alterations associated with cancer
and cell death processes in this study is likely due to the
PAs. As discussed above, PAs produce hepatotoxicity and
carcinogenesis in experimental animals and humans.
Functional analysis with Ingenuity Pathway Analysis
showed that comfrey which contains 9 PAs [7-9] altered
many more genes involved in cancer related pathways
than riddelliine. The expressions of 387 cancer-related
genes were significantly altered after comfrey exposure
and the expressions of 84 cancer-related genes were signif-
icantly changed by riddelliine treatment. These genes are
involved in the many functions associated with different
stages of carcinogenesis. A large number of genes related
to both treatments may indicate the PAs' carcinogenic
insults. Table 3 shows the detailed information of 42
genes whose expressions were significantly altered by
both riddelliine and comfrey treatments. These common
cancer-related genes include genes involved in apoptosis
and cell death, invasion, cell growth, cell morphology,
and cell cycle. Figure 6 shows the strong correlation
between the log2 fold-changes in gene expression caused
by the two treatments; only two of the genes were regu-
lated in the opposite directions. These results also indicate
that the carcinogenicity of comfrey is generated from PAs.
Most of genes involved in apoptosis (Cdkn1c, Egr1, Fas,
Gdf15, Hgf, Hrasls3, Hspa1a, Lama5, Smox, Tnfsf10) were
up-regulated and may be explained by the removal of cells
damaged by PAs. For example, Egr1  (early growth
response 1), whose expression increased 12- and 2-fold
over the control with comfrey and riddelliine treatments,
respectively, has the ability to function in numerous
capacities, including differentiation, growth, growth inhi-
bition, and apoptosis depending on the cell type and the
stimulus. In response to stress, Egr1 displays a remarkable
functional similarity to p53  and p73  [38] and may be
involved in protection of the cell against the toxicity of
these compounds. We also observed that comfrey and rid-
delliine significantly up-regulated Hspa1a, the gene
encoding heat shock protein (HSP) 70 family members.
High levels of inducible HSP70s prevent stress-induced
apoptosis and block caspase activity, mitochondrial dam-
age, and nuclear fragmentation [39]. These genes may all
be involved in repair and protection of the cell against the
damage caused by the PAs.
Table 2: The major relevant functions altered by both comfrey 
and riddelliine treatments in liver
Function category Number of processes
Cancer 35
Cell death 35
Small molecule biochemistry 17
Cell morphology 14





Comparison of fold-change of drug metabolizing genes  (DMG) whose expression was altered by both comfrey and  riddelliine treatments Figure 4
Comparison of fold-change of drug metabolizing 
genes (DMG) whose expression was altered by both 
comfrey and riddelliine treatments. Twenty-two DMGs 
detailed in Table 1 were commonly regulated by comfrey and 
riddelliine.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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Among the common cancer-related genes, the expressions
of two genes (Fez1 and Mgat5) were altered in opposite
directions (down-regulated by comfrey and up-regulated
by riddelliine). Mgat5  encodes N-acetylglucosaminyl-
transferase V (GlcNAc-TV), the Golgi enzyme required in
the N-glycan processing pathway that modifies glycopro-
teins, including the cytokine receptors. Mgat5 gene expres-
sion is up-regulated by Ras pathway activation [40]. In
Mgat5-/- mice, tumor latency is longer and metastasis is
reduced compared with Mgat5+/+ mice [41]. FEZ1 (Fascic-
ulation and elongation protein zeta-1) is a tumor suppres-
sor gene that maps to chromosome 8p22, a chromosomal
region frequently deleted in many human malignancies.
The FEZ1 gene is expressed almost ubiquitously in normal
tissues, and is prone to inactivation in human cancer [42].
In addition, introduction of FEZ1 into Fez1-negative can-
cer cells results in suppression of tumorigenicity and
reduced cell growth with accumulation of cells at late S-
G2/M stage of the cell cycle [43]. These two genes appear
to be important in the carcinogenesis process and the dif-
ferences in their expression in the two treatment groups
may be an indication that the livers in the two groups are
in different stages of the carcinogenic process. Alterna-
tively, this may reflect the contribution of other compo-
nents in comfrey.
Conclusion
Previously we found that the mutagenicity of comfrey was
associated with the PAs contained in the plant. Therefore,
we suggested that the toxicity and carcinogenicity of
comfrey resulted from these PAs. In this study, we ana-
lyzed gene expression profiles in the liver of rats treated
with riddelliine, a widely studied genotoxic PA and a
proven rodent mutagen and carcinogen, and comfrey, an
herbal tea that contains as many as nine PAs. We used the
systematic approaches of HCA, PCA, functional analysis,
and biological process analysis. Although there were large
differences between the genes whose expression was sig-
nificantly altered by these two treatments, there are com-
mon genes and function processes which may be
indicative of effects due to PAs. In support of this is the
finding that there were strong correlations between the
gene expression fold-change alterations caused by the two
treatments, in particular, drug metabolizing genes and
cancer-related genes. These results suggest that comfrey
and riddelliine may share common mechanism(s) of car-
cinogenesis, and further support our hypothesis that PAs
are the main active components for carcinogenesis of
comfrey.
Materials and methods
Treatments with comfrey and riddelliine
The details on the description of the in vivo portion of this
study has been described previously [26,32]. Briefly, Big
Blue Fisher 344 transgenic rats were fed with a diet con-
taining 8% comfrey root for 12 weeks or gavaged with 1
mg/kg riddelliine 5 times a week for 12 weeks. One day
after the last treatment, 6 rats from each vehicle control,
comfrey-treated, and riddelliine-treated groups were sacri-
ficed, and the livers were isolated and stored at -80°C for
mutagenesis and microarray analysis. Big Blue transgenic
rats were obtained from Taconic Laboratories (German-
town, NY) through purchase from Stratagene (La Jolla,
CA). All animal procedures followed the recommenda-
tions of the NCTR Institutional Animal Care and Use
Committee for the handling, maintenance, treatment,
and sacrifice of the rats.
Microarray processing
The detailed description of the microarray processing of
this study has been reported previously [32,33]. Briefly,
total RNA was isolated from liver tissues of 6 control, 6
comfrey-fed, and 6 riddelliine-treated rats using an RNe-
asy system (Qiagen, Chatsworth, CA). All RNA targets
were labeled using the Applied Biosystems RT-IVT Labe-
ling Kit Version 2.0. Digoxigenin labeled cRNA targets
were hybridized to Applied Biosystems Rat Whole
Genome Survey Microarrays using the Applied Biosystems
Chemiluminescent Detection Kit. Images were auto-grid-
ded and the chemiluminescent signals were quantified,
corrected for background, and finally, spot- and spatially-
normalized using the Applied Biosystems 1700 Chemilu-
minescent Microarray Analyzer software version 1.1.
Microarray data analysis
Raw microarray intensity data from the Applied Biosys-
tems' Rat Genome Survey Microarray, which is a one
Number of regulated function processes significantly altered  (P < 0.01) by comfrey and riddelliine treatments Figure 5
Number of regulated function processes significantly 
altered (P < 0.01) by comfrey and riddelliine treat-
ments. The color in green refers to the number of function 
processes that were significantly altered by both riddelliine 
and comfrey.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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Table 3: Genes involved in carcinogenesis altered by comfrey and riddelliine treatments in liver
Gene symbol Gene description Locus link ID Fold changea
Comfrey Riddelliine
AKR1C3 aldo-keto reductase family 1, member C3 171516 -4.9 -39.5
AR androgen receptor (dihydrotestosterone receptor) 24208 -13.6 -19.6
ARHGDIG Rho GDP dissociation inhibitor (GDI) gamma 14570 -8.9 -12.1
C5ORF13 chromosome 5 open reading frame 13 338475 -7.5 -7.6
CAST Calpastatin (includes EG:831) 25403 -3.3 -5.4
CD36 CD36 molecule (thrombospondin receptor) 29184 3.3 7.9
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 246060 5.1 2.7
CHEK1 CHK1 checkpoint homolog (S. pombe) 140583 2.1 2.5
CREM cAMP responsive element modulator 25620 -2.6 -3.3
DOK1 docking protein 1, 62kDa (downstream of tyrosine kinase 1) 13448 4.5 2.9
ECGF1 endothelial cell growth factor 1 (platelet-derived) 72962 -6.7 -2.8
EGR1 early growth response 1 24330 12.2 2.2
FABP2 fatty acid binding protein 2 25598 3.3 2.7
FAS Fas (TNF receptor superfamily, member 6) 246097 3.3 3.2
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) 81730 -3.2 2.9
FUT1 fucosyltransferase 1 81919 -4.8 -6.9
FYN FYN oncogene related to SRC, FGR, YES 25150 4.3 2.8
GDF15 growth differentiation factor 15 29455 4.8 2.3
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 24446 3.6 2.4
HRASLS3 HRAS-like suppressor 3 24913 3.0 4.0
HSPA1A heat shock 70kDa protein 1A 3303 4.1 8.1
ID1 inhibitor of DNA binding 1, 25261 3.9 2.2
IGFBP2 insulin-like growth factor binding protein 2, 36kDa 25662 3.2 15.7
ITGA4 integrin, alpha 4 (antigen CD49D) 16401 5.4 2.1
LAMA5 laminin, alpha 5 3911 37.5 2.1
LIMK2 LIM domain kinase 2 29524 4.1 2.0
MGAT5 mannoside acetylglucosaminyltransferase 5 65271 -2.2 2.1
MT1A metallothionein 1A (functional) 24567 5.8 12.2
NCR1 natural cytotoxicity triggering receptor 1 117547 2.5 61.7
NQO1 NAD(P)H dehydrogenase, quinone 1 24314 5.0 2.6
PPARG peroxisome proliferative activated receptor, gamma 25664 -2.6 -5.3
PRLR prolactin receptor 24684 29.8 284.4
PTK6 PTK6 protein tyrosine kinase 6 20459 -16.7 -3.7
RTN4 reticulon 4 83765 6.2 3.4
SERPINA5 serpin peptidase inhibitor, clade A, member 5 65051 -3.1 -2.2
SMOX spermine oxidase 228608 2.0 2.3
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 20440 -2.7 -5.7
ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 25280 -6.8 -6.8
TIMP3 TIMP metallopeptidase inhibitor 3 25358 2.1 2.1
TNF tumor necrosis factor (TNF superfamily, member 2) 24835 -4.2 -24.5
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 246775 2.4 2.6
TUBG1 tubulin, gamma 1 252921 -3.2 -4.2
aThe symbol of minus (-) means down-regulation, and the P-value for all genes is less than 0.01.BMC Bioinformatics 2007, 8(Suppl 7):S22 http://www.biomedcentral.com/1471-2105/8/S7/S22
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channel microarray with chemiluminescence detection
and contains 26,857 probes, were normalized with quan-
tile normalization which is recommended by the manu-
facturer. The normalized data were then input to
ArrayTrack, a software system developed by the NCTR for
the management, analysis, visualization and interpreta-
tion of microarray data [44]. The identification of differ-
entially expressed genes based on fold-change and t-tests
cutoffs, and HCA and PCA were conducted within
ArrayTrack. Ingenuity Pathway Analysis (Mountain View,
CA) was used for network and function analysis.
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